镰状细胞病的治愈选择:单倍体移植还是基因治疗?
本文对比了单倍体造血干细胞移植与基因治疗作为镰状细胞病治愈手段的现状与前景。单倍体移植扩大了供者池且近期数据显示总生存率高、毒性有限、GVHD控制良好;多种基因治疗策略正进入临床试验且初步数据积极。目前单倍体移植因数据更成熟可能为优选,但基因治疗正缩小差距,最终选择需综合疗效、移植风险、安全性、患者状态与偏好、成本及可及性等因素。
要点
- 单倍体移植使几乎所有镰状细胞病患者可获得治愈性供者来源
- 基因治疗初步数据积极,理论上可避免GVHD相关风险
- 当前单倍体移植数据更成熟,但基因治疗正快速缩小差距
核心结论
- 单倍体移植与基因治疗均为镰状细胞病的治愈性策略,目前单倍体移植因数据更成熟可能为优选,但基因治疗正缩小差距并可能最终成为更优选择。
研究设计与样本
- 本文为综述,比较单倍体造血干细胞移植与基因治疗作为镰状细胞病治愈策略的现状与前景。
主要发现
- 单倍体移植将供者池扩大至几乎所有镰状细胞病患者,近期数据显示总生存率高、毒性有限、急慢性GVHD有效减少。
- 多种基因治疗策略正进入临床试验,初步数据显示其成功,理论上为所有患者提供另一种无需承受GVHD相关患病与死亡的治愈策略。
临床怎么用
- 当前选择治愈策略时,单倍体移植可优先考虑,但需综合疗效、移植患病与死亡、安全性、患者疾病状态与偏好、成本及可及性等因素个体化决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Haematopoietic stem cell transplantation (HSCT) is curative in sickle cell disease (SCD); however, the lack of available matched donors makes this therapy out of reach for the majority of patients with SCD. Alternative donor sources such as haploidentical HSCT expand the donor pool to nearly all patients with SCD, with recent data showing high overall survival, limited toxicities, and effective reduction in acute and chronic graft-versus-host disease (GVHD). Simultaneously, multiple gene therapy strategies are entering clinical trials with preliminary data showing their success, theoretically offering all patients yet another curative strategy without the morbidity and mortality of GVHD. As improvements are made for alternative donors in the allogeneic setting and as data emerge from gene therapy trials, the optimal curative strategy for any individual patient with SCD will be determined by many critical factors including efficacy, transplant morbidity and mortality, safety, patient disease status and preference, cost and applicability. Haploidentical may be the preferred choice now based mostly on availability of data; however, gene therapy is closing the gap and may ultimately prove to be the better option. Progress in both strategies, however, makes cure more attainable for the individual with SCD.
引用
- Leonard A, Tisdale J, Abraham A, et al. Curative options for sickle cell disease: haploidentical stem cell transplantation or gene therapy? Br J Haematol. 2020. PMID: 32034776. doi:10.1111/bjh.16437
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。